Conference abstractPublished 27 Jun 2016
Interchangeability of Biological Drug Products
University of Toronto, Canada
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Conditions for the interchangeability of biological and small-molecule drug products are very different. Small-molecule drugs are well defined and can be exactly reproduced. If their products, brand-name and generic, are declared to be bioequivalent then they are (most frequently but not always) therapeutically equivalent and can be substituted and interchanged. In contrast, biological drugs are structurally and functionally complicated, can be only imitated but not identically reproduced, are sensitive to various environmental and manufacturing conditions, are subject to biological and immunological influences. Consequently, only high similarity but not equivalence can be demonstrated, in various respects, between the marketed and new products. However, even the stated biosimilarity of two products does not enable their interchangeability in terms of switching and alternating. For this, additional conditions must be satisfied. There has been no agreement on these conditions among the various jurisdictions. Legislation in the United States, and also FDA, has set general principles. The European EMA has issued biosimilarity guidelines for several drug products. The latter permit in some cases possible interchangeability even though the issue is under the judgment of the member states. It is desirable to develop a general, scientific basis for the evaluation of interchangeability of biological drug products. Suitable study designs are considered, an approach for the assessment of switching and alternating across multiple domains is presented, and a possible criterion for the interchangeability of biological products is described.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Laszlo Endrenyi”